Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Bio Warns It Needs Cash to Continue Operations Beyond September

NEW YORK (GenomeWeb News) – Pressure BioSciences said in its quarterly earnings document that it may not be able to fund its operations beyond next month.

In its Form 10-Q filed with the US Securities and Exchange Commission on Thursday, the South Easton, Mass.-based company said that as of June 30, it had $113,663 in cash and cash equivalents and warned that it will need "substantial additional capital" to fund operations beyond the end of September 2013.

"In the event that we are unable to obtain financing on acceptable terms, or at all, we will likely be required to cease our operations, pursue a plan to sell our operating assets, or otherwise modify our business strategy, which could materially harm our future business prospects," it said.

On Thursday, the company reported a 10 percent increase in revenues for its second quarter. However, Pressure Bio has been under financial pressure for a while now. In May, it warned of similar cash problems, saying at the time it might not be able to maintain operations beyond May.

In its 10-Q, Pressure Bio said that it signed agreements to borrow a total of $875,000 from three lenders in April through June. Through Aug. 1, it received $542,500 under the agreements, though "[t]here is no guaranty that the company will receive the amounts remaining under these agreements."

Pressure Bio added that last week it received $160,000 in a one-year note from an existing shareholder. Terms of that note included "18 percent annual interest, one three-year warrant to acquire 160,000 shares of common stock at $0.40 per share, and a right to convert the note into the next equity financing."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.